Treating ‘Untreatable’ Diseases: Gene Therapy and the Patent Battlefield
Gene therapy is revolutionising the field of molecular medicine and the capabilities of therapeutic approaches Recent developments demonstrate the potential for gene therapy to address some of… read more…
Mathys & Squire Partners featured in IAM Strategy 300 Global Leaders 2026
Three Mathys & Squire Partners, Anna Gregson, Dani Kramer, and Martin MacLean, have been recognised in the 2026 edition of IAM Strategy 300 Global Leaders The guide acknowledges those that… read more…
Continuing trend of cutting-edge medical technology being used in the cosmetics industry
Partner Samantha Moodie and Associate Clare Pratt have been featured in Life Sciences IP Review and Aesthetic Medicine providing commentary on the increased use of biotherapeutic molecules in… read more…
Mathys & Squire will be at BIP Asia 2025
Mathys & Squire will be at the BIP Asia 2025 in Hong Kong on the 4th to the 5th of December Associate Rogen Leung will be attending the Business of IP (BIP) Asia Forum 2025, which… read more…
Mathys & Squire will be at the Open-i conference
Mathys & Squire will be at Open-i in Zurich, Switzerland on the 27th of November Partner Andrea McShane will be attending the Open-i conference, “The Swiss Innovation Platform”, taking… read more…
Mathys & Squire will be at the CIPA Life Sciences Conference 2025
Mathys & Squire will be at the CIPA Life Sciences Conference 2025 in Birmingham, UK from the 20th to the 21st of November Partner Anna Gregson, Managing Associates Olivia Creemer and Tom… read more…
